Back 09 Oct 2025

Singapore Institute of Advanced Medicine Holdings Ltd: Material Variances Identified Between FY2025 Audited and Unaudited Financial Statements

Link: https://links.sgx.com/1.0.0/corporate-announcements/F1HDSZK4739D6224/85ac33198e29902bb2480bce01fff88786d7e74d384fe24243085d72ff7edb9a

Summary:

  • Board announces significant differences between unaudited and audited figures for FY2025 following final audit completion, with details shared per SGX Catalist Rule 704(5).

  • Biggest variance: Other gains/(losses) reduced by S$893,631 after reclassification of fair value gains and modification gains on loans from profit/loss to equity (no impact to total equity).

  • Loss before tax increased to S$27.05 million in audited accounts, up S$893,631 from unaudited results; loss per share slightly higher at 2.57 Singapore cents.

  • Other reserves and accumulated losses adjusted to reflect reclassification; total equity remains unchanged.

  • Net cash generated from financing activities reclassified to exclude restricted cash, now reported under financing activities instead of cash equivalents (no effect on overall cash/bank balances).

  • Board also clarifies financial effects of proposed transactions (Caterine debt conversion, placement of new shares): projected loss per share reduced after equity infusions from these transactions.

  • Shareholders are advised to read full audited results for FY2025 and exercise caution before making investment decisions; listed on SGX Catalist, IPO sponsored by PrimePartners Corporate Finance.

  • Announcement issued by CEO Dr Djeng Shih Kien, dated 9 October 2025, includes standard SGX disclaimer and sponsor contact.

  1. https://links.sgx.com/FileOpen/251009%20SIAMH%20-%20Material%20Variances%20FY2025.ashx?App=Announcement&FileID=863492